ClinicalTrials.gg
Enrolling by invitationNCT07675538HITADHDUpdated Jun 30, 2026

High Intensity Training for Adults With ADHD in Specialised Mental Health Care

An interventional study of High intensity training in Attention Deficit Disorder With Hyperactivity (ADHD), sponsored by Solli Distriktspsykiatriske Senter. Enrolling by invitation at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Solli Distriktspsykiatriske Senter · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Attention Deficit Disorder with Hyperactivity with a site in Norway — 4 open to participants now, 7 under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Norway.

Planned enrollment
23rd of 25
30 · median 100
Started
2026
the only one that year
No phase
17 of 30
3 open now
Registered
30th of 30
by date

Among the 30 studies in Attention Deficit Disorder with Hyperactivity with a site in Norway, this one is the 23rd largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2026, is one of 17 with no phase, and was the 30th registered.

Attention Deficit Disorder with Hyperactivity

1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

4 of the 30 studies in Attention Deficit Disorder with Hyperactivity with a site in Norway are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Attention Deficit Disorder with Hyperactivity with a site in Norway, or all of them as a file.
02

Study summary

Attention-Deficit/Hyperactivity Disorder (ADHD) is a lifelong neurodevelopmental disorder characterised by persistent symptoms of inattention, hyperactivity, and impulsivity. According to the DSM-5, these symptoms must be present for at least six months, have an onset in childhood, and result in significant impairment in multiple life domains. Although ADHD may be limited to childhood in some cases, most individuals continue to have symptoms and impairments in varying degrees in adult life. The prevalence of persistent ADHD among adults is estimated to be approximately 2.58%, depending on diagnostic criteria and sample selection. The increasing awareness of ADHD has led to a marked increase in referrals to mental health services, which places greater demands on the development of effective and accessible treatment options for this group.

Pharmacological treatment, particularly the use of stimulants, is a common intervention for adults with ADHD and has been shown to be effective for many. However, there are also side effects associated with drug treatment, and there is a need for more evidence-based non-drug alternatives. In addition, discontinuation of medication is common in ADHD treatment. Psychological interventions include psychoeducation and cognitive behaviour therapy, as well as more specialised approaches based on Dialectical Behaviour Therapy and Goal Management Training, which aim to improve executive functions. Whilst pharmacotherapy and psychotherapeutic interventions help some people with ADHD, not all people experience favourable outcomes, which calls for alternative treatment approaches. Interventions targeting the core symptoms of ADHD, executive functions, and behaviour are particularly relevant to treatment provision.

One approach to improving executive functioning that has received increasing attention is physical exercise. Studies have shown that physical activity can have a positive effect on cognitive function, executive control, and behaviour in children and adolescents with ADHD. Physical exercise may also be applied as treatment for comorbid factors common in ADHD, such as mood disorders and multiple long-term physical conditions. Despite increasing interest in physical activity as a treatment modality, research on physical exercise for adults with ADHD is still limited. The findings from studies on younger age groups point to the potential for similar effects in adults, but more research is needed to examine the effects of physical exercise as a targeted intervention in the adult population with ADHD.

Among the different types of physical activity, high-intensity interval training (HIIT) has gained promise for mental health. Due to its rapid, alternating, and fast-paced style, it could prove useful for those with ADHD. However, research on high-intensity interval training interventions (HIIT) in this population is scarce. To address these unanswered questions, this project will conduct a feasibility trial for a randomised controlled trial (RCT) to assess the feasibility and acceptability of HIIT among people with ADHD.

03

Conditions studied

  • Attention Deficit Disorder With Hyperactivity (ADHD)

Keywords

  • ADHD
  • Physical exercise
  • High intensity training
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Above 18 years
  • An ADHD diagnosis (F90.0 in the ICD-10)

Exclusion criteria

Exclusion Criteria:

  • Psychiatric conditions not compatible with participation incl. ongoing psychotic episode, mania, acute suicidality etc.,
  • Physical conditions precluding participation in physical testing and/or exercise
  • Comprehensive ongoing substance use determined by the Alcohol Use Disorders IdentificationTest (AUDIT; Babor et al., 2001) and the Drug Use Disorder Identification Test (DUDIT; Berman et al., 2003). An AUDIT cut-off score of 16 (high risk), and/or DUDIT score of 20 (high risk) will lead to screening with MINI International Neuropsychiatric Interview (Lecrubier etal., 1997; Sheehan et al., 1998).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    High intensity training

    Fourteen weeks of high intensity strenght and endurance training after a protocol.

    Behavioral: High intensity training

Interventions

  • BehavioralHigh intensity training

    14 weeks of high intensity training of strenght and endurace.

06

What researchers measure

Primary outcomes

  1. Feasibility of the intervention: Recruitment rate

    Recruitment rate: Proportion of eligible participants who agree to participate in the study ((Number of participants recruited/Number of eligible participants) x 100). Aim: \>50%.

    Time frame: through study completion, an average of 1 year

  2. Feasibility measure: Retention rate

    Retention rate: Proportion of participants who remain in the study until completion ((Number of participants completing the study/Number of participants enrolled) x 100). Aim: \>80%.

    Time frame: through study completion, an average of 1 year

  3. Feasibility measure: Dropout rate

    Dropout rate: How many participants dropped out after inclusion. Registration of reasons of dropout.

    Time frame: through study completion, an average of 1 year

  4. Feasibility measure: Compliance

    Compliance: How many sessions each participant attended. Registration of reasons of sessions not attended.

    Time frame: through study completion, an average of 1 year

  5. Feasibility measure: Adherence to protocol

    Adherence to protocol: How many elements in the physical exercise program were conducted in each session. Physical exercise diary for registration of load and intensity of strength- and endurance training, respectively. Aim: \>80%. Also, registration of adherence to the total test protocol.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. In depth interview

    Participants will be invited to an in-depth interview lasting approx. 45 minutes, after the treatment intervention. The aim is to explore experiences with physical exercise in relation to core symptoms of ADHD. A semi-structured interview protocol with open questions and additional probes is used to promote exploratory dialogue on the participants experience with participation. All interviews will be audio recorded and transcribed verbatim. By comparing the individual accounts, we want to identify both patterns of commonalities and differences in participants' experiences, providing important descriptions of patient experiences that may contribute to detect challenges with the intervention that can be utilised for further development and implementation.

    Time frame: Participants are inviteted within two weeks after ending their participation

  2. General Ability - WAIS-IV

    Six sub tests from the general ability test Wecshler Adult Intelligence Scale will be used to assess General Ability Index, Verbal Comprehension Index and Perceptual Reasoning Index. The six subtests are: Block Design, Similarities, Matrix Reasoning, Vocabulary, Digit Span and Coding.

    Time frame: Within two weeks before initating intervention.

  3. The Adult ADHD Self-Report Scale

    The Adult ADHD Self-Report Scale (ASRS) is a patient-reported outcome measure assessing the frequency and severity of adult ADHD symptoms. Items are rated on a 5-point Likert scale (0-4), with higher total scores reflecting greater ADHD symptom severity. Lower scores reflect fewer self-reported ADHD symptoms.

    Time frame: Within two weeks before initating intervention. Within two weeks after ending intervention.

  4. The Working Memory Questionnaire

    The Working Memory Questionnaire (WMQ) is a patient-reported outcome measure designed to assess everyday difficulties related to working memory functioning. It evaluates the frequency of memory-related problems experienced in daily life, including difficulties with remembering information, maintaining attention, following instructions, and managing cognitive tasks. The WMQ consists of items rated on a Likert-type scale, where participants indicate how often they experience specific working memory difficulties. A total score is calculated by summing item responses. Higher scores indicate greater perceived working memory difficulties and a higher level of impairment in everyday cognitive functioning. Lower scores indicate fewer reported working memory problems and better perceived working memory functioning. The total WMQ score is calculated by summing responses across items (with item scoring depen

    Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.

  5. The Generalized Anxiety Disorder-7

    The Generalized Anxiety Disorder-7 (GAD-7) is a patient-reported outcome measure assessing anxiety symptom severity. Items are scored from 0-3 based on symptom frequency over the previous two weeks, producing a total score from 0-21. Higher scores indicate greater anxiety symptom severity, while lower scores indicate fewer anxiety symptoms

    Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.

  6. The Patient Health Questionnaire-9

    The Patient Health Questionnaire-9 (PHQ-9) is a patient-reported outcome measure assessing depressive symptom severity. Items are scored from 0-3 based on symptom frequency over the previous two weeks, producing a total score from 0-27. Higher scores indicate greater depressive symptom severity, while lower scores indicate fewer depressive symptoms.

    Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.

  7. The Bergen Insomnia Scale

    The Bergen Insomnia Scale (BIS) is a patient-reported outcome measure assessing insomnia symptoms and sleep-related impairment. Six items are rated from 0-7 according to symptom frequency over the previous month, producing a total score from 0-42. Higher scores indicate greater insomnia symptom severity, while lower scores indicate fewer insomnia symptoms.

    Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.

  8. The International Physical Activity Questionnaire

    The International Physical Activity Questionnaire (IPAQ) is a patient-reported outcome measure assessing physical activity and sedentary behavior. It measures frequency and duration of walking, moderate-intensity, and vigorous-intensity activities over a specified recall period. Scores are calculated as MET-minutes/week, with higher scores indicating greater physical activity and lower scores indicating less physical activity.

    Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.

  9. The Work and Social Adjustment Scale

    The Work and Social Adjustment Scale (WSAS) is a patient-reported outcome measure assessing functional impairment associated with a health condition. Five items are rated from 0-8, producing a total score from 0-40. Higher scores indicate greater impairment in work, social, and daily functioning, while lower scores indicate better functioning.

    Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.

  10. The Adult ADHD Quality of Life

    The Adult ADHD Quality of Life (AAQoL) is a validated self-report questionnaire designed to assess health-related quality of life in adults with attention-deficit/hyperactivity disorder (ADHD). The instrument evaluates the impact of ADHD symptoms on daily functioning and well-being across multiple domains, including life productivity, psychological health, relationships, and outlook. The AAQoL consists of 29 items, each rated on a Likert-type scale reflecting the frequency or severity of difficulties experienced over a specified recall period. Item responses are combined and transformed into domain scores and an overall total score. Item responses are aggregated and converted to standardized scores ranging from \*\*0 to 100\*\* for the total scale and each domain. Higher scores indicate better health-related quality of life, while lower scores indicate poorer quality of life and greater ADHD-related f

    Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.

  11. Credibility/Expectancy Questionnaire

    The Credibility/Expectancy Questionnaire (CEQ) is a patient-reported measure assessing perceived treatment credibility and expectancy for improvement. It consists of 5 items where patients rate themselves on a likert scale from 0-10. It produces a total scores, with higher scores indicating greater perceived credibility and stronger expectations of treatment benefit.

    Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.

  12. The Negative Effects Questionnaire - Short Form

    The Negative Effects Questionnaire - Short Form (NEQ-S) is a patient-reported outcome measure assessing perceived negative or unwanted effects of an intervention. Higher scores indicate a greater number and/or severity of self-reported adverse effects.

    Time frame: Within two weeks after completion of the last session.

  13. The Wechsler Memory Scale - Third Edition

    The Wechsler Memory Scale - Third Edition (WMS-III) Spatial Memory subtest is a clinician-administered measure of visuospatial memory. Standardized age-adjusted scores are derived, with higher scores indicating better spatial memory performance and lower scores indicating poorer spatial memory.

    Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.

  14. D-KEFS Trail Making Test

    The D-KEFS Trail Making Test is a clinician-administered measure of executive function assessing visual scanning, processing speed, and cognitive flexibility. Performance is measured by time to completion and standardized scaled scores, with higher scores (and faster completion times) indicating better executive functioning."

    Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.

  15. D-KEFS Color-Word Interference Test

    The D-KEFS Color-Word Interference Test is a clinician-administered measure of executive function assessing response inhibition and cognitive flexibility. Performance is measured by time to completion and standardized scaled scores, with higher scores (and faster completion times) indicating better executive functioning.

    Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.

  16. Maximal strenght

    Maximal strength is assessed using the one-repetition maximum (1RM) test for lower-body and upper-body strength. In this study, maximal lower-body strength is assessed using a leg strength exercise (e.g., leg press or squat depending on protocol), and upper-body strength is assessed using the bench press. The primary outcome is the maximal load lifted successfully for one repetition, recorded in kilograms (kg). Separate 1RM values are obtained for leg strength and bench press. Higher scores: Indicate greater maximal muscular strength and neuromuscular performance in the tested muscle groups. Lower score

    Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.

  17. Maximal oxygen uptake

    Maximal oxygen uptake (VO₂max) is an estimate of the maximum rate at which oxygen can be utilized during intense aerobic exercise and is a key indicator of cardiorespiratory fitness. In this study, VO₂max is estimated using the Myworkout GO mobile application (Helgerud et al., 2022), which derives VO₂max from performance data collected during a standardized treadmill-based interval protocol (4×4 endurance session). The estimation is based on recorded treadmill speed and incline during the exercise session, which are used to model aerobic capacity according to validated predictive algorithms. VO₂max is reported as an estimated continuous variable in milliliters of oxygen per kilogram of body weight per minute (mL·kg-¹·min-¹). Higher values indicate greater aerobic capacity and cardiorespiratory fitness, while lower values indicate reduced aerobic fitness.

    Time frame: Within two weeks before first intervention session and within two weeks after completion of the last session.

07

Study locations

1 site
  • Solli DPS and Kronstad DPS
    Bergen, Norway
08

References and documents

Individual participant data

Plan to share: No — This has not been applied for to the ethical Committee.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 16 months is below that.

Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jun 30, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 30, 2027
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07675538
Lead sponsor
Solli Distriktspsykiatriske Senter
Collaborators
Helse-Bergen HF
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Feb 1, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jun 30, 2026

Study contacts

Kristine Sirevåg, PhD
principal investigator · Solli DPS

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion